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Background: Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder
characterised by the symptoms of inattention, impulsivity and hyperactivity. ADHD was once perceived as a
condition of childhood only; however increasing evidence has highlighted the existence of ADHD in older
adolescents and adults. Estimates for the prevalence of ADHD in adults range from 2.5–4%. Few data exist on the
prescribing trends of the stimulants methylphenidate and dexamfetamine, and the non-stimulant atomoxetine in
the UK. The aim of this study was to investigate the annual prevalence and incidence of pharmacologically treated
ADHD in children, adolescents and adults in UK primary care.
Methods: The Health Improvement Network (THIN) database was used to identify all patients aged over 6 years
with a diagnosis of ADHD/hyperkinetic disorder and a prescription for methylphenidate, dexamfetamine or
atomoxetine from 2003–2008. Annual prevalence and incidence of pharmacologically treated ADHD were
calculated by age category and sex.
Results: The source population comprised 3,529,615 patients (48.9% male). A total of 118,929 prescriptions were
recorded for the 4,530 patients in the pharmacologically treated ADHD cohort during the 6-year study. Prevalence
(per 1000 persons in the mid-year THIN population) increased within each age category from 2003 to 2008 [6–
12 years: from 4.8 (95% CI: 4.5–5.1) to 9.2 (95% CI: 8.8–9.6); 13–17 years: from 3.6 (95% CI: 3.3–3.9) to 7.4 (95% CI:
7.0–7.8); 18–24 years: from 0.3 (95% CI: 0.2–0.3) to 1.1 (95% CI: 1.0–1.3); 25–45 years: from 0.02 (95% CI: 0.01–0.03) to
0.08 (95% CI: 0.06–0.10); >45 years: from 0.01 (95% CI: 0.00–0.01) to 0.02 (95% CI: 0.01–0.03). Whilst male patients
aged 6-12 years had the highest prevalence; the relative increase in prescribing was higher amongst female
patients of the same age - the increase in prevalence in females aged 6–12 years was 2.1 fold compared to an
increase of 1.9 fold for their male counterparts. Prevalence of treated ADHD decreased with increasing age.
Incidence (per 1000 persons at risk in the mid-year THIN population) was highest for children aged 6–12 years.
Conclusions: A trend of increasing prescribing prevalence of ADHD drug treatment was observed over the period
2003–2008. Prevalence of prescribing to adult patients increased; however the numbers treated are much lower
than published estimates of the prevalence of ADHD. This study has added to the limited knowledge on ADHD
prescribing in primary care, particularly in the area of drug treatment in adulthood.* Correspondence: s.mccarthy@ucc.ie
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Attention Deficit Hyperactivity Disorder (ADHD) is a
common neurodevelopmental disorder characterised by
the symptoms of inattention, impulsivity and hyperactiv-
ity. The prevalence of ADHD in school-aged children
and adolescents in the United Kingdom (UK) using the
broader Diagnostic and Statistical Manual of Mental Dis-
orders, 4th Edition (DSM-IV) criteria is estimated at 5%
[1]. The prevalence of hyperkinetic disorder (HKD) in
children and young people (5–16 years), defined by the
narrower International Classification of Disease 10th Re-
vision (ICD-10) criteria is estimated at 1.5% [2].
ADHD/HKD affects children and adolescents in vari-
ous ways and to different extents; however the conse-
quences of the condition generally impact greatly on
patients, their families and those around them. Un-
treated ADHD/HKD is frequently associated with under-
achievement in school, harm to relationships with
family, teachers and friends, increased rates of criminal-
ity and accidents; and the development of comorbid psy-
chiatric symptoms including oppositionality, anxiety,
depression and substance misuse [3,4].
Treatments and interventions for ADHD/HKD are
varied and include in the main, psychological therapies
and pharmacological treatment [5]. When drug treat-
ment is considered appropriate for the patient, the cen-
tral nervous system stimulants methylphenidate (MPH)
and dexamfetamine (DEX) and the non-stimulant ato-
moxetine (ATM) are recommended in the UK [1,5].
These drug treatments have been shown to improve the
core symptoms of inattention, hyperactivity and impul-
sivity [5]. Methylphenidate, considered to be first-line
therapy, has been used for over 50 years for the treat-
ment of ADHD/HKD and is licensed in the UK for use
as part of a comprehensive treatment programme for
ADHD/HKD in children (over 6 years of age) and ado-
lescents when remedial measures alone prove insuffi-
cient [6].
Only one previous study known to us has estimated
incidence rates and the prevalence for pharmacologically
treated ADHD in boys aged 5–14 years in the UK from
1996–2001 [7]. This study reported a prevalence of 5.3
per 1000 boys in 1999.
ADHD/HKD was once perceived as a condition of
childhood only; however an increase in the evidence has
highlighted the existence of ADHD/HKD in older ado-
lescents and adults [5]. Estimates for the prevalence of
the condition in adults range from 2.5–4% [4,8-10].
Whilst there is evidence of persistence of ADHD/HKD
from childhood into adulthood [11], there are limited
data on the treatment patterns of ADHD/HKD in adults
in routine clinical practice. A cohort study in the UK
examined the prevalence of prescribing of MPH, DEX
and ATM in adolescents and young adults aged 15–21 years from 1999–2006 and identified a 6-fold increase
in prescribing over this time. Prevalence of prescribing
of these drugs to the older patients was significantly
lower [12].
Currently, in the UK, ConcertaW XL (prolonged-release
MPH) is the only stimulant which has a license for use in
the treatment of ADHD/HKD in adults, and only as a con-
tinuation treatment in patients whose symptoms have per-
sisted from adolescence into adulthood and have shown
clear benefit from treatment [6]. The non-stimulant ATM
is also only indicated as continuation treatment in adults
who started their treatment with this medication in child-
hood [13]. The published NICE guidelines (2008) [5] and
the British Association for Psychopharmacology guidelines
[14] strongly advocate that appropriate treatments, psycho-
logical or pharmacological, should be provided for adults
with ADHD/HKD.
While it is recognised that the use of medications to
treat childhood ADHD/HKD has increased in the last
decade or so, which may be coincident with the publica-
tion of the NICE Technology Appraisal on methylphen-
idate in 2000 [15], there are limited data to support this
and there are some concerns that ADHD/HKD treat-
ments might be used inappropriately or over-prescribed
[16]. To our knowledge only two studies have looked at
pharmacologically treated ADHD in UK primary care
[7,12]. These studies are limited as they report data from
over a decade ago [7] and in restricted age groups;
younger children [7] and older adolescents and young
adults [12]. Therefore, this study aims to address the
gaps in the literature and to estimate the prevalence and
incidence of pharmacologically treated ADHD (MPH,
DEX and ATM) in children (over 6 years), adolescents
and adults in UK primary care.
Methods
Design and source population
A retrospective cohort study was performed using data
from The Health Improvement Network (THIN). THIN
contains anonymised computerised information entered
by general practitioners (GPs) in the UK. With coverage
of approximately 5.7% of the UK population (2009),
practices that use the database are broadly representative
of practices in the UK for patients’ characteristics [17].
GPs participating in THIN are trained to record infor-
mation using the Vision general practice system (In
Practice Systems; London, UK) and the validity of data
on the database for research has been supported by a
number of studies [18-20]. Data recorded in THIN in-
clude patient demographics, details from GP visits, diag-
noses from specialist referrals and hospital admissions,
and the results of laboratory tests. Prescriptions issued
by the GP are directly generated from the computer.
The Read classification is used to code specific diagnoses
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based on data from the MULTILEX classification is used
to code drugs. Prescriptions issued by specialists are not
coded onto the database but information on them may
be available as free-text comments.
We identified all individuals who were aged 6 years
and over and were registered with a GP practice on the
THIN database between January 1, 2003 and December
31, 2008 (the study period). Age of individuals on the
THIN database is calculated from the month and year of
birth up to the age of 15 years. Once individuals reach
the age of 15 years, age is calculated using the year of
birth only (i.e. 1st January of that year).
The ‘start date’ for these individuals was calculated
from the latest of three dates: the date they registered
with the GP practice, the date the GP practice started to
use the Vision practice system or the date of the prac-
tice’s Acceptable Mortality Reporting, used as a quality
indicator for the practice. This information was obtained
from patients’ records on THIN. This ‘start date’ could
precede the start of the study period or could occur dur-
ing the study period. Individuals were only included in
the source population if they had an observation period
of at least 12 months from their ‘start date’ and were
registered during the study period.
Identification of the pharmacologically treated ADHD
cohort
The pharmacologically treated ADHD cohort comprised
patients with both a prescription coded for a study drug
during the study period and a diagnosis of ADHD coded
at any time on the database (identified from Read codes).
As THIN is a patient-records database, there is no re-
quirement to have diagnoses coded every year. Therefore
no time restriction was placed on when the diagnosis
was recorded in relation to when the study drugs were
prescribed. These patients were identified by examining
the records of all individuals in the source population
after each patient’s ‘start date’. The final pharmacologic-
ally treated ADHD cohort comprised 4,530 individuals.
Prevalence calculation
The annual prevalence of pharmacologically treated
ADHD was calculated by summing all patients withTable 1 Total number of prescriptions of methylphenidate, d
2008
2003 2004
Total Number of Prescriptions 11,441 14,763
Methylphenidate (n, % of total prescriptions) 11,053 (96.6) 14,233 (96.4)
Dexamfetamine (n, % of total prescriptions) 388 (3.4) 352 (2.4)
Atomoxetine (n, % of total prescriptions) N/A* 178 (1.2)
*N/A: no prescriptions for atomoxetine were issued on the database to a patient inADHD and a prescription for MPH, DEX or ATM
(the study drugs) in a particular study year. This num-
ber was divided by the total number of individuals in
the mid-year (1st July) source population in that calen-
dar year. The annual prevalence was expressed per
1000 patients. Age-specific and sex-specific prevalences
were calculated.
Incidence calculation
The first 12 months following the patient’s ‘start date’
was used as a screening period. If the first prescrip-
tion for MPH, DEX or ATM was identified during
this 12-month screening period, it was not treated as the
incident prescription. Patients prescribed ADHD drugs
during this 12-month screening period were not included
in the risk pool. Incident prescriptions were defined as a
first prescription identified after this 12-month ‘screening
period’ and hence the patient was identified as an incident
patient during the year in which the first prescription was
identified. Only those patients defined as incident patients
during the study period were included in the numerator
of this study.
Incidence denominator
The denominator comprised individuals from the source
population who were considered ‘at risk’ i.e. did not have
a diagnosis of ADHD and a prescription for a study
drug. Therefore, individuals’ data contributed to the de-
nominator only after the first 12-month screening period
following their ‘start date’. Patients who were prescribed
ADHD medication before the study period were
excluded from the denominator during the study period.
Likewise, patients who were prescribed ADHD medica-
tions during the study period were excluded from the in-
cidence denominator of subsequent years.
Annual incidence was calculated by dividing the num-
ber of incident patients by the total number of persons
in the source population ‘at risk’ in the mid-year (1st
July) population.
Data analysis
Prevalence and incidence were calculated for each year
of the study period 2003–2008 and stratified into differ-
ent age bands (6–12 years, 13–17 years, 18–24 years,examfetamine and atomoxetine recorded from 2003 to
2005 2006 2007 2008 Total
17,906 22,108 26,205 26,506 118,929
16,058 (89.7) 19,710 (89.2) 23,255 (88.7) 23,476 (88.6) 107,785 (90.6)
433 (2.4) 487 (2.2) 494 (1.9) 484 (1.8) 2,638 (2.2)
1,415 (7.9) 1,911 (8.6) 2,456 (9.4) 2,546 (9.6) 8506 (7.2)
this study in the year 2003; it was marketed in the UK starting 2004.
Table 2 Annual prevalence (2003–2008) of pharmacologically treated ADHD (methylphenidate, dexamfetamine and
atomoxetine) by age category and gender
Age Category Year 2003 2004 2005 2006 2007 2008
Total Prevalence*1000
(Males and Females≥6 years)
0.709 0.862 1.014 1.203 1.365 1.403
95% Cl (lb)*1000 0.676 0.825 0.975 1.161 1.320 1.358
95% Cl (ub)*1000 0.743 0.899 1.054 1.246 1.411 1.449
6-12 years
Female Prevalence*1000 1.339 1.642 2.042 2.310 2.775 2.769
95% Cl (lb)*1000 1.131 1.411 1.784 2.034 2.470 2.464
95% Cl (ub)*1000 1.574 1.900 2.327 2.613 3.108 3.101
Male Prevalence*1000 8.147 9.758 11.133 13.224 15.432 15.321
95% Cl (lb)*1000 7.634 9.195 10.532 12.566 14.716 14.607
95% Cl (ub)*1000 8.685 10.346 11.759 13.907 16.174 16.061
Total Prevalence*1000 4.825 5.795 6.688 7.886 9.241 9.181
95% Cl (lb)*1000 4.543 5.485 6.355 7.522 8.844 8.786
95% Cl (ub)*1000 5.121 6.119 7.034 8.262 9.651 9.590
13-17 years
Female Prevalence*1000 0.635 0.947 1.106 1.446 1.767 2.002
95% Cl (lb)*1000 0.465 0.742 0.890 1.201 1.497 1.714
95% Cl (ub)*1000 0.847 1.191 1.360 1.727 2.071 2.325
Male Prevalence*1000 6.250 7.535 9.104 11.027 11.752 12.569
95% Cl (lb)*1000 5.719 6.963 8.485 10.350 11.054 11.845
95% Cl (ub)*1000 6.818 8.141 9.757 11.737 12.483 13.325
Total Prevalence*1000 3.608 4.404 5.265 6.378 6.865 7.396
95% Cl (lb)*1000 3.314 4.087 4.925 6.008 6.484 6.999
95% Cl (ub)*1000 3.921 4.739 5.622 6.765 7.264 7.810
18-24 years
Female Prevalence*1000 0.118 0.116 0.112 0.244 0.337 0.335
95% Cl (lb)*1000 0.059 0.058 0.056 0.158 0.236 0.237
95% Cl (ub)*1000 0.211 0.207 0.200 0.361 0.466 0.460
Male Prevalence*1000 0.396 0.521 0.845 0.943 1.385 1.876
95% Cl (lb)*1000 0.283 0.391 0.679 0.770 1.178 1.637
95% Cl (ub)*1000 0.540 0.680 1.038 1.142 1.619 2.140
Total Prevalence*1000 0.263 0.327 0.493 0.607 0.878 1.122
95% Cl (lb)*1000 0.196 0.253 0.402 0.507 0.759 0.989
95% Cl (ub)*1000 0.346 0.417 0.599 0.721 1.010 1.267
25-45 years
Female Prevalence*1000 0.008 0.026 0.028 0.040 0.045 0.052
95% Cl (lb)*1000 0.002 0.012 0.014 0.023 0.027 0.032
95% Cl (ub)*1000 0.023 0.047 0.050 0.065 0.071 0.079
Male Prevalence*1000 0.025 0.038 0.052 0.074 0.095 0.105
95% Cl (lb)*1000 0.012 0.021 0.032 0.050 0.068 0.076
95% Cl (ub)*1000 0.046 0.062 0.079 0.105 0.130 0.141
Total Prevalence*1000 0.017 0.032 0.040 0.057 0.070 0.079
95% Cl (lb)*1000 0.009 0.021 0.027 0.042 0.053 0.061
95% Cl (ub)*1000 0.028 0.047 0.056 0.076 0.091 0.100
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Table 2 Annual prevalence (2003–2008) of pharmacologically treated ADHD (methylphenidate, dexamfetamine and
atomoxetine) by age category and gender (Continued)
>45 years
Female Prevalence*1000 0.007 0.011 0.007 0.010 0.010 0.011
95% Cl (lb)*1000 0.002 0.004 0.002 0.004 0.004 0.005
95% Cl (ub)*1000 0.018 0.023 0.018 0.022 0.022 0.024
Male Prevalence*1000 0.008 0.008 0.015 0.015 0.020 0.027
95% Cl (lb)*1000 0.002 0.002 0.007 0.006 0.010 0.015
95% Cl (ub)*1000 0.020 0.020 0.030 0.029 0.036 0.044
Total Prevalence*1000 0.008 0.009 0.011 0.012 0.015 0.019
95% Cl (lb)*1000 0.003 0.004 0.006 0.007 0.009 0.012
95% Cl (ub)*1000 0.015 0.017 0.019 0.021 0.024 0.028
CI (Confidence Interval), lb (lower boundary) and ub (upper boundary).
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tical analyses were performed.
Data manipulation and analysis were conducted using
Stata/MP version 11.0 (StataCorp, College Station, Texas,
United States).
Ethical approval
Ethical approval for this study was granted by the
Cambridgeshire 4 Research Ethics Committee (ref: 09/
H0305/81).
Results
The source population comprised 3,529,615 patients
(48.9% male). A total of 118,929 prescriptions were
recorded for the 4,530 patients aged ≥ 6 years in the
pharmacologically treated ADHD cohort during the 6-
year study period with a median number of prescriptions
per patient of 17 [95% CI: 16, 18]. The average length of
time that the 4,530 patients were registered on the data-
base was 8.5 years [SD 4.7 years, range 1.0-21.1 years].
MPH was the drug most frequently prescribed during
the study period followed by ATM and DEX (Table 1).
Prevalence of treated ADHD
There was a trend for the annual prevalence estimates to
increase year on year from 2003 to 2008 (Table 2). Fig-
ure 1 demonstrates this increase in prevalence estimates
over the study period and also that the prevalence esti-
mates decreased with increasing age. The prevalence
estimates approximately doubled between 2003 and
2008, in children and adolescents and those patients
over 45 years old; however the largest increase was
observed in adults aged 18–24 years and 25–45 years,
with an approximate 4-fold increase in prevalence
estimates.
These patterns were also evident when the data were
further stratified by gender (Table 2). For both genders
and across all age categories (with the exception ofpatients aged over 45 years), the annual prevalence esti-
mates increased from 2003–2008, with the prevalence
being lower in female patients for all age categories. It is
observed from Table 2 that the prevalence of prescribing
to males and females over 45 years was very low. The
number of patients aged 45 years and over in the patient
dataset ranged from 8 in 2003 to 22 in 2008.
For male and female children aged 6–12 years, the
prevalence increased 1.88 fold and 2.07 fold respectively.
Prevalence estimates increased 2.01 fold for adolescent
males aged 13–17 years, whereas prevalence estimates
increased 3.15 fold for their female counterparts. For
male and female patients aged 25–45 years the preva-
lence estimates increased 4.2 and 6.5 fold respectively
during the study period. Table 3 presents the ratio of
male to female prescribing prevalence and the ratio of
males to females registered on the database across each
of the age categories. Whilst the proportions of males
and females on the database in the various age categor-
ies and over time were similar, a decrease in the ratio of
prescribing prevalence estimates was observed for chil-
dren aged 6–12 years, adolescents aged 13–17 years and
adults aged 25–45 years. The data suggest that for these
age categories, the rate of increase in prevalence was
greater in females than males. Conversely, for young
adults aged 18–24 years and for adults aged over
45 years, the ratio of prescribing increased thereby indi-
cating that the rate of increase in prescribing to males
was greater than that observed in females.Incidence of treated ADHD
The source population for incidence calculations was
3,226,266 (49.3% male). A total of 2,343 patients were in-
cident during the study period. Incidence of prescribing
is illustrated in Figure 2. The analysis shows that the inci-
dence estimates were highest for children (6–12 years)
and decreased with increasing age, being very low in
adults. The incidence estimates were higher in 2008 than
Figure 1 Prevalence of pharmacologically treated attention deficit hyperactivity disorder (methylphenidate, dexamfetamine or
atomoxetine) in patients aged 6-years and over in UK general practice (with 95% confidence intervals).
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mates for children and for adolescents (13–17 years)
were highest in 2006. The incidence estimates were
much higher for young adults (18–24 years) in 2004, the
year in which atomoxetine entered the market, than in
all other years except for 2008. When the data were
stratified by gender, the incidence estimates were shownTable 3 Ratio of male to female prescribing prevalence by ag
registered on the database
Age Category 2003 2004
Prevalence 6–12 years 6.085 5.942
Registered on database 6–2 years 1.050 1.048
Prevalence 13–17 years 9.838 7.955
Registered on database 13–17 years 1.125 1.104
Prevalence 18–24 years 3.355 4.492
Registered on database 18–24 years 1.084 1.093
Prevalence 25–45 years 3.252 1.461
Registered on database 25–45 years 1.025 1.026
Prevalence >45 years 1.108 0.736
Registered on database >45 years 0.903 0.906to be much lower in females than in males (Table 4).
Similarly to prevalence estimates, the incidence estimates
increased proportionally more for female children and
adolescents than for the males of these age categories.
However for young adult males (aged 18–24 years) the
increase was 7.23 fold compared to 1.62 fold for young
adult female patients.e category and study year and ratio of males to females
2005 2006 2007 2008
5.451 5.725 5.560 5.534
1.045 1.045 1.044 1.044
8.228 7.625 6.652 6.277
1.083 1.061 1.043 1.043
7.549 3.856 4.117 5.602
1.084 1.079 1.066 1.043
1.867 1.835 2.120 2.020
1.023 1.022 1.022 1.014
2.202 1.462 2.004 2.339
0.908 0.912 0.915 0.916
Figure 2 Incidence of pharmacologically treated attention deficit hyperactivity disorder (methylphenidate, dexamfetamine or
atomoxetine) in patients aged 6-years and over in UK general practice (with 95% confidence intervals).
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In this study, estimates for the prevalence of MPH, DEX
and ATM prescribing were calculated for the period,
2003 to 2008, using data from THIN database. It was
observed that prevalence of prescribing increased over
this time, with a ~2-fold increase for children and ado-
lescents, and a 4–5-fold increase for adults. Incidence of
prescribing showed similar patterns whereby the inci-
dence of prescribing was greater in children and
declined in adulthood.
School-age children and adolescents
Overall, prevalence increased over the study period from
4.83 to 9.18 per 1000 patients aged 6–12 years. The
highest prevalence of prescribing in this study was to
boys aged 6–12 years (15.32 per 1000 boys aged 6–
12 years in 2008). Prescribing to male patients in this
age category was higher than to female patients (6:1 in
2003; 5.5:1 in 2008). These findings are in line with fig-
ures reported in the literature, which report differences
in prescribing between the genders ranging from a ratio
of 2:1 to 9 [21]. It is not known to what extent this is a
true behavioural gender difference and how much is due
to factors such as the under-diagnosis and under-reporting of the condition in females. Interestingly, the
relative increase in prevalence over the study for chil-
dren 6–12 years was slightly higher in female patients
compared to male patients (2.1 compared with 1.9 times
increase). A similar observation was reported by Cox
et al., who reported that in the US from 2002 to 2005,
the rate of growth of ADHD drug prescribing to females
was double that of males [22].
Treatment prevalence for adolescents aged 13–17 years
followed a similar pattern whereby the overall preva-
lence doubled over the study period. The driver of this
increase was prescribing to adolescent girls (3.15 in-
crease over the 6 year period) although actual prevalence
was again higher in male patients.
To our knowledge, only one previous study has exam-
ined the use of these drugs in children in the UK [7].
The authors reported on the incidence and prevalence
of MPH and DEX in boys aged 5–14 years from 1996–
2001. This study reported a prevalence of 5.3 per 1000
boys in 1999.
A study from the Netherlands used computerised
pharmacy dispensing records to examine the prevalence
and incidence of psychotropic medications in Dutch
children from 1995 to 1999. The highest prevalence
Table 4 Annual incidence (2003–2008) of pharmacologically treated ADHD (methylphenidate, dexamfetamine and
atomoxetine) by age category and gender
Age Category Year 2003 2004 2005 2006 2007 2008
6-12 years
Female Incidence*1000 0.272 0.388 0.358 0.425 0.433 0.424
95% Cl (lb)*1000 0.181 0.277 0.252 0.309 0.314 0.307
95% Cl (ub)*1000 0.393 0.528 0.494 0.571 0.581 0.571
Male Incidence*1000 1.982 2.036 2.013 2.476 2.331 2.101
95% Cl (lb)*1000 1.725 1.776 1.753 3.188 2.049 1.833
95% Cl (ub)*1000 2.267 2.325 2.300 2.793 2.642 2.397
Total Incidence*1000 1.145 1.229 1.201 1.470 1.400 1.278
95% Cl (lb)*1000 1.005 1.084 1.058 1.311 1.243 1.128
95% Cl (ub)*1000 1.300 1.388 1.359 1.643 1.570 1.441
13-17 years
Female Incidence*1000 0.102 0.178 0.168 0.224 0.318 0.270
95% Cl (lb)*1000 0.0471 0.095 0.090 0.133 0.208 0.169
95% Cl (ub)*1000 0.210 0.304 0.288 0.354 0.465 0.409
Male Incidence*1000 0.666 1.160 1.063 1.174 1.052 0.977
95% Cl (lb)*1000 0.496 0.937 0.852 0.954 0.845 0.777
95% Cl (ub)*1000 0.876 1.422 1.309 1.429 1.295 1.212
Total Incidence*1000 0.400 0.691 0.631 0.710 0.691 0.629
95% Cl (lb)*1000 0.303 0.566 0.514 0.587 0.571 0.514
95% Cl (ub)*1000 0.516 0.836 0.767 0.851 0.829 0.762
18-24 years
Female Incidence*1000 0.013 0.037 0.000 0.023 0.022 0.021
95% Cl (lb)*1000 0.000 0.008 0.000 0.003 0.003 0.002
95% Cl (ub)*1000 0.071 0.108 0.044 0.082 0.079 0.074
Male Incidence*1000 0.022 0.096 0.041 0.070 0.087 0.159
95% Cl (lb)*1000 0.003 0.044 0.011 0.028 0.040 0.092
95% Cl (ub)*1000 0.080 0.182 0.106 0.144 0.165 0.254
Total Incidence*1000 0.018 0.069 0.022 0.048 0.056 0.093
95% Cl (lb)*1000 0.004 0.036 0.006 0.022 0.028 0.056
95% Cl (ub)*1000 0.052 0.120 0.057 0.091 0.101 0.145
25-45 years
Female Incidence*1000 0.000 0.009 0.006 0.011 0.003 0.016
95% Cl (lb)*1000 0.000 0.002 0.001 0.003 0.000 0.006
95% Cl (ub)*1000 0.011 0.025 0.020 0.028 0.015 0.036
Male Incidence*1000 0.008 0.011 0.022 0.013 0.019 0.027
95% Cl (lb)*1000 0.002 0.003 0.009 0.004 0.008 0.013
95% Cl (ub)*1000 0.024 0.028 0.043 0.031 0.039 0.049
Total Incidence*1000 0.004 0.010 0.014 0.013 0.011 0.022
95% Cl (lb)*1000 0.001 0.004 0.007 0.006 0.005 0.012
95% Cl (ub)*1000 0.012 0.020 0.025 0.023 0.021 0.035
>45 years
Female Incidence*1000 0.004 0.000 0.000 0.002 0.002 0.000
95% Cl (lb)*1000 0.000 0.000 0.000 0.000 0.000 0.000
95% Cl (ub)*1000 0.013 0.007 0.007 0.10 0.010 0.006
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Table 4 Annual incidence (2003–2008) of pharmacologically treated ADHD (methylphenidate, dexamfetamine and
atomoxetine) by age category and gender (Continued)
Male Incidence*1000 0.000 0.000 0.004 0.002 0.004 0.009
95% Cl (lb)*1000 0.000 0.000 0.000 0.000 0.000 0.003
95% Cl (ub)*1000 0.008 0.007 0.014 0.011 0.014 0.021
Total Incidence*1000 0.002 0.000 0.002 0.002 0.003 0.004
95% Cl (lb)*1000 0.000 0.000 0.000 0.000 0.001 0.001
95% Cl (ub)*1000 0.007 0.004 0.007 0.007 0.008 0.010
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was 13.9 per 1000 children [23]. More recently, a retro-
spective analysis was conducted by Hodgkins and col-
leagues to estimate the incidence and prevalence of
children, aged 6–17 years, receiving initial pharmaco-
therapy for ADHD between 2000 and 2007 from a large
sample representative of the general population of the
Netherlands [24]. Data extrapolated from the PHARMO
database to the Netherlands population demonstrated
an increase in yearly incidence from 30 per 10,000 in
the year 2000 to 75 per 10,000 in the year 2007. Preva-
lence increased from 110 per 10,000 in 2000 to 210 per
10,000 in 2007 [24].
A study examining prescribing trends for stimulants
from 1992 to 1998 using North Carolina Medicaid pre-
scription claim files reported an increase in prevalence
from 44 per 1000 patients in 1992 to 95 per 1000
patients in 1998 in children aged 6–14 years. The
authors of this paper acknowledged that the rates
observed in their study were much higher than other
studies reported; however they do not speculate as to
why this is the case [25].
More recent studies from the US include a study by
Zuvekas et al. who used the Medical Expenditure Panel
Survey database to report prevalence of stimulant use
from 1997 to 2002 in children aged less than 19 years
[26]. The prevalence increased from 27 per 1000 patients
(95% CI: 23–31 per 1000) in 1997 to 29 per 1000 patients
(95% CI: 25–33 per 1000) in 2002. They also reported
the highest use of stimulants in children aged 6–12 years.
Cox et al. used ambulatory prescription claims data of
children aged 5–19 years from 2002 to 2005 and over
this period reported a growth in prevalence of ADHD
medications of 40.4% [22].
These utilisation studies suggest that especially in the
US, the prevalence of stimulant use increased substan-
tially during the last decade.
The current study has demonstrated a trend of in-
creasing prevalence of pharmacological treatments in
the UK, throughout the study period; however the high-
est prevalence figure reported of 15.4 per 1000 male
patients aged 6–12 years is in line with or below those
reported in both the Netherlands and the US.More importantly this figure is also lower than the
global prevalence of ADHD in children or that of hyper-
kinetic disorders in the UK, which were recently esti-
mated to be 5% and 1.5% respectively [2,27]. This is
relevant as current NICE clinical guidelines recommend
that for school-age children and young people with se-
vere ADHD (hyperkinetic disorder), drug treatment
should be offered as the first-line treatment and that
medication will also be appropriate for patients with
moderate levels of impairment who have refused non-
drug interventions, or whose symptoms have not
responded sufficiently to parent-training/education pro-
grammes or group psychological treatment [5].
Adults
Population surveys in adult populations estimate the
prevalence of ADHD in adults to be between 2.5 and 4%
[4,8-10]. Whilst not all patients will require pharmaco-
logical intervention, NICE recommends that it should be
the first-line treatment unless the person would prefer a
psychological approach [5]. The results of this study sug-
gest a trend of increasing prevalence of prescribing of
ADHD drugs to adult patients; however the numbers re-
main much lower than the estimated prevalence of the
condition. There may be several reasons for this includ-
ing that earlier NICE guidelines in 2000 [15] indicated
that medication should be tailed off in adolescence and
the lack of licensed medicines for the treatment of
ADHD in adulthood. It is expected that with the recom-
mendation in the current NICE guidelines [5] for
pharmacological treatment of adult ADHD, the increase
in prevalence seen in this study will increase further and
this may better reflect the prevalence of the disorder in
a few years' time.
Strengths and limitations
A significant strength of the study was the use of a large
database such as THIN which provided primary care
data on a cohort of over 4500 patients. THIN has been
used widely in epidemiological research, including stud-
ies on mental health [28,29]. The use of THIN data
allowed us to capture what is actually happening under
normal conditions of clinical practice, rather than in
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NICE guidelines recommend that although medications
should be initiated by healthcare professionals with ap-
propriate expertise in ADHD, GPs may continue pre-
scribing and monitoring of medications; thus the use of
a general practice database is a suitable data source for
identifying and examining ADHD prescribing patterns.
Nevertheless, these data might underestimate the overall
prescribing rates in the UK since in some regions of the
country specialist mental health teams or paediatricians
remain the main prescribers and some GP practices will
not prescribe medications for ADHD. This might par-
ticularly influence the estimates for prescribing to adults,
since prescribing practice for those over the age of
18 years is still not well established in the UK and
prescribing by specialists rather than GPs is still the
norm in many regions.
A limitation of the data is that detailed information on
the diagnoses was not readily accessible; therefore it was
not possible to determine the severity of ADHD in the
patients identified. An inclusion criterion for the study
was that patients were required to be registered on the
database during the study period 2003–2008 and have a
minimum of one year of registration on the database.
However, patients may have registered on the database at
various points during this period or before this period.
Therefore, the amount of follow-up time for patients
registered later on the database may have been less than
those registered earlier in the study period. For incidence
calculations, patients prescribed ADHD drugs during this
12-month screening period were not included in the risk
pool for subsequent years of the study. This resulted in
varying look-back periods, in that in 2003, patients inci-
dent in 2002 were removed, whereas in 2008, six years of
incident patients were removed. However, as the num-
bers of incident patients are small relative to the denom-
inator, it is unlikely that this would influence reported
rates significantly. A potential bias in the data when com-
paring prevalence between 2003 and 2008 is that some
patients may contribute data in both years. Data from
such patients would not contribute to the change in
prevalence. This potential overlap in the cohorts was not
taken into account when comparing the prevalence be-
tween 2003 and 2008.
The issue of over-prescribing of ADHD medicines was
outside the remit of this study, as studies which have
looked at this question have identified patients with an
ADHD diagnosis who do and do not receive medication
and/or psychological treatments, along with patients
who receive medication but who do not meet the diag-
nostic criteria for ADHD [30,31]. The detailed specialist
records required to examine this are not routinely avail-
able for all patients on a general practice database such
as THIN and so the current study cannot answer thequestion as to whether the stimulants (MPH, DEX and
ATM) are over-prescribed. However, despite the increase
in prescribing observed over the study period, the differ-
ence between the prevalence of the condition reported in
the literature and the prevalence in this study of prescrib-
ing of these drugs to those with ADHD does provide
some assurance that it is unlikely that these drugs are
over-used in the UK. ADHD pharmacological treatments
are generally accepted to have a favourable risk/benefit
ratio but long-term safety of these drugs should continue
to be monitored [32,33]. This has been identified as a pri-
ority for research for the European Union who have com-
missioned the ADDUCE study (http://adhd-adduce.org),
as part of the Seventh Framework Programme for Re-
search and Technological Development, to examine the
long-term safety of stimulants.
Conclusions
Epidemiological data from the THIN database revealed a
trend of increasing prescribing prevalence of ADHD drug
treatment over the period 2003–2008 overall and for all
age groups. Whilst male patients aged 6–12 years had
the highest prevalence, the relative increase in prescrib-
ing was higher amongst female patients of the same age.
Prevalence of prescribing of ADHD drugs to adult
patients increased over the six-year period; however the
numbers remain much lower than the published esti-
mates of the prevalence of the condition. Of the three
study drugs, MPH had the highest prevalence, followed
by ATM. DEX use in children declined over the study
period. Incidence of ADHD drug prescribing was very
low across all age categories.
This study has added to the existing knowledge on
ADHD prescribing patterns in primary care; in particu-
lar to the area of ADHD drug treatment in adulthood.
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